BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1675 related articles for article (PubMed ID: 25708133)

  • 1. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.
    Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N
    Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population.
    Ruhl CE; Everhart JE
    Am J Gastroenterol; 2013 Jun; 108(6):952-8. PubMed ID: 23545713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.
    Qureshi K; Abrams GA
    Clin Obes; 2016 Apr; 6(2):117-23. PubMed ID: 26856683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based study on the prevalence of NASH using scores validated against liver histology.
    Hyysalo J; Männistö VT; Zhou Y; Arola J; Kärjä V; Leivonen M; Juuti A; Jaser N; Lallukka S; Käkelä P; Venesmaa S; Simonen M; Saltevo J; Moilanen L; Korpi-Hyövalti E; Keinänen-Kiukaanniemi S; Oksa H; Orho-Melander M; Valenti L; Fargion S; Pihlajamäki J; Peltonen M; Yki-Järvinen H
    J Hepatol; 2014 Apr; 60(4):839-46. PubMed ID: 24333862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of non alcoholic fatty liver and Non alcoholic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan.
    Shah AS; Khan S; Rahim H; Chishti KA; Khan AG
    Pak J Pharm Sci; 2018 Jan; 31(1):193-198. PubMed ID: 29348103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease.
    Yilmaz Y; Ayyildiz T; Akin H; Colak Y; Ozturk O; Senates E; Tuncer I; Dolar E
    Gut Liver; 2014 May; 8(3):313-7. PubMed ID: 24827629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
    Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
    Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease.
    Lee YC; Wu JS; Yang YC; Chang CS; Lu FH; Chang CJ
    Scand J Gastroenterol; 2014 Aug; 49(8):1001-6. PubMed ID: 24989169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
    Chan WK; Ida NH; Cheah PL; Goh KL
    J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.